Mosaic ImmunoEngineering Inc

NEW
OTCPK:CPMV (USA)   Ordinary Shares
$ 0.060 +0.0060 (+11.11%) 10:09 PM EST
At Loss
Market Cap:
$ 435.00K
Enterprise V:
$ 2.12M
Volume:
6.20K
Avg Vol (2M):
822.00
Trade In:
Volume:
6.20K
At Loss
Avg Vol (2M):
822.00

Business Description

Mosaic ImmunoEngineering Inc
NAICS : 325412 SIC : 2834
ISIN : US61945M1018

Share Class Description:

CPMV: Ordinary Shares

Total Employee Number:

7
Description
Mosaic ImmunoEngineering Inc is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. It has a single operating segment for the purposes of assessing performance and making operating decisions. The company is pursuing new product candidates and platforms to build a product pipeline based on its deep understanding of immunotherapies.

Financial Strength

Name Current Vs Industry Vs History
Equity-to-Asset
-765.1
Debt-to-Equity
-0.22
Debt-to-EBITDA
-2.83
Piotroski F-Score
3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate
35.4
3-Year EPS without NRI Growth Rate
33.2
3-Year FCF Growth Rate
46
3-Year Book Growth Rate
-15.2

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI
18.96
9-Day RSI
21.52
14-Day RSI
23.88
3-1 Month Momentum %
-9.59
6-1 Month Momentum %
17.22
12-1 Month Momentum %
68.5

Liquidity Ratio

Name Current Vs Industry Vs History

Dividend & Buy Back

Name Current Vs Industry Vs History
Shareholder Yield %
-2.88

Profitability Rank

Name Current Vs Industry Vs History
ROA %
-1412.86
ROIC %
-13.22
3-Year ROIIC %
100.2
Moat Score
2
Tariff Resilience Score
7
Name Current Vs Industry Vs History
EV-to-EBIT
-3.55
EV-to-EBITDA
-3.55
EV-to-FCF
-24.63
Earnings Yield (Greenblatt) %
-28.17
FCF Yield %
-19.82

Financials

CPMV's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:CPMV

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Mosaic ImmunoEngineering Inc Executives

Details

GF Valueâ„¢

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -0.09
Beta -0.0941
3-Year Sharpe Ratio 0.5
3-Year Sortino Ratio 0.96
Volatility % 190.53
14-Day RSI 23.88
14-Day ATR ($) 0.095699
20-Day SMA ($) 0.565945
12-1 Month Momentum % 68.5
52-Week Range ($) 0.054 - 1.05
Shares Outstanding (Mil) 7.24

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Mosaic ImmunoEngineering Inc Filings

Filing Date Document Date Form
No Filing Data

Mosaic ImmunoEngineering Inc Stock Events

Financials Calendars
Event Date Price ($)
0.002:1 Stock Split 2020-12-02 2.55 (+2.00%)
Show
Entries

Mosaic ImmunoEngineering Inc Frequently Asked Questions

What is Mosaic ImmunoEngineering Inc(CPMV)'s stock price today?
The current price of CPMV is $0.06. The 52 week high of CPMV is $1.05 and 52 week low is $0.05.
When is next earnings date of Mosaic ImmunoEngineering Inc(CPMV)?
The next earnings date of Mosaic ImmunoEngineering Inc(CPMV) is .
Does Mosaic ImmunoEngineering Inc(CPMV) pay dividends? If so, how much?
Mosaic ImmunoEngineering Inc(CPMV) does not pay dividend.

Guru Commentaries on OTCPK:CPMV

No articles.

Press Release

Subject Date
Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc. 2024-04-29
UPDATE: Mosaic ImmunoEngineering's Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company's Novel Immuno-Oncology Platform 2022-10-31
Mosaic ImmunoEngineering's Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company's Novel Immuno-Oncology Plat-form 2022-10-31
Mosaic ImmunoEngineering Announces Completion of Exclusive Technology License Agreement with Case Western Reserve University 2022-05-05
Newly Published Data Further Support Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 in Combination with OX40 Checkpoint Treatment in Melanoma 2022-02-02
Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation 2021-11-01
Mosaic ImmunoEngineering Announces Upcoming Presentation at the 23rd Annual SoCalBio Conference 2021-10-20
Spotlight Presentation at the World Molecular Imaging Congress Highlights Mosaic ImmunoEngineering's Immuno-Oncology and Modular Vaccine Platform Candidates 2021-10-12
Mosaic ImmunoEngineering Expands Immuno-Oncology Platform Through New Technology Licensing Agreement with the University of California San Diego 2021-10-06
Upcoming Presentation at the World Molecular Imaging Congress to Highlight Mosaic ImmunoEngineering's Lead Immuno-Oncology and Modular Vaccine Platform COVID-19 Vaccine Candidates 2021-10-01
10/Page

Articles on Mosaic ImmunoEngineering Inc

No articles.

Headlines

See More
  • 1
No news.
  • 1